BYSI · BeyondSpring Inc.
AI read · Neutral
The AI's read
This leaves BeyondSpring without the subsidiary that indirectly held its Bulin interests, and brings no cash into the company. The investor must complete the China part of the trial, and BeyondSpring can access the resulting clinical data. Those terms point in different directions, and the filing gives no value for either side to show which matters more.